Search

Kosta D Steliou

from Natick, MA
Age ~75
Get Report
Also known as:
Stelio Kosta
Related to:
Venetia M StelliouVenetia M Stelliou, 45
Connected to:
Mark T Steliotes, 65Dana L Stelitano, 53Renae A Stelitano, 52Darlene G Steljes, 73Mark D Stelk, 75Sean M Stelken, 35Andy Stell, 44Casey N Stell, 44Cheryl L Stell, 47Chi W Stell, 68

Kosta Steliou Phones & Addresses

  • Natick, MA
  • 9 Hawthorne St, Boston, MA 02114 (617) 227-8520
  • 590 Commonwealth Ave, Boston, MA 02215
  • Cambridge, MA
  • Goffstown, NH
  • Watertown, MA
  • Nashua, NH
  • 9 Hawthorne Pl APT 4R, Boston, MA 02114 (617) 285-1563

Work

Company: Boston university school of medicine Jan 2008 Position: Professor, cancer center

Education

Degree: Doctorates, Doctor of Philosophy School / High School: Mcgill University

Industries

Pharmaceuticals

Resumes

Resumes

Kosta Steliou Photo 1

Professor, Cancer Center

View page
Location:
Boston, MA
Industry:
Pharmaceuticals
Work:
Boston University School of Medicine
Professor, Cancer Center
Boston University School of Medicine
Research Emeritus Professor of Pharmacology
Phenomatrix
Chairman
Université De Montréal 1979 - 1994
Professor
Boston University 1979 - 1994
Professor, Cancer Center
Education:
Mcgill University
Doctorates, Doctor of Philosophy

Business Records

Name / Title
Company / Classification
Phones & Addresses
Kosta Steliou
Director
MASSACHUSETTS ASSOCIATION OF SCHOLARS, INC
120 Foster St, Cambridge, MA 02138
9 Hawthorne Pl, Boston, MA 02114

Publications

Us Patents

Mitochondria-Targeting Antioxidant Therapeutics

View page
US Patent:
20100210569, Aug 19, 2010
Filed:
Feb 12, 2010
Appl. No.:
12/658575
Inventors:
Kosta Steliou - Boston MA, US
International Classification:
A61K 47/48
C07H 3/02
C07C 229/06
C12N 5/00
US Classification:
514 23, 536 111, 560170, 560125, 560147, 552653, 549398, 5483037, 435375, 514546, 514529, 514167, 514387, 514458, 514474, 514356
Abstract:
The instant invention constitutes an unique subject matter as a whole which has four individual aspects: (1) a class of chiral, non-racemic, synthetic carnitinoid analog carrier molecules which constitute biocompatible transport compounds not found in nature; (2) a subsequently formed, mitochondria-targeting, coupled antioxidant-carrier complex comprising an antioxidant reversibly attached to and releasable from the synthetic carrier molecule; (3) a method for introducing a biologically active antioxidant into the interior of mitochondria of a living cell for subsequent reaction with such reactive oxygen species may then be present; and (4) a system for delivering a biologically active antioxidant to the interior of mitochondria within a living cell.

Drug Mitochondrial Targeting Agents

View page
US Patent:
63166526, Nov 13, 2001
Filed:
Jun 6, 1995
Appl. No.:
8/468844
Inventors:
Kosta Steliou - Boston MA
International Classification:
C07F 110
C07F 112
C07F 1500
C07F 300
US Classification:
556 42
Abstract:
The invention relates to novel targeting drug agents that are targeted for entry into the mitochondria. More specifically, the agents are cisplatin derivatives called mitoplatins which are useful as anti-tumor agents. Mitoplatins are named for their targeting to the mitochondrial DNA via the carnitine-acylcarnitine translocase system. The invention also relates to methods of synthesizing mitoplatins, compositions of matter containing mitoplatins and methods of using the mitoplatins.
Control profile
Kosta D Steliou from Natick, MA, age ~75 Get Report